Investigational Drug Information for ASTX660
✉ Email this page to a colleague
What is the development status for investigational drug ASTX660?
ASTX660 is an investigational drug.
There have been 8 clinical trials for ASTX660.
The most recent clinical trial was a Phase 1 trial, which was initiated on July 1st 2015.
The most common disease conditions in clinical trials are Lymphoma, Lymphoma, T-Cell, and Lymphoma, T-Cell, Peripheral. The leading clinical trial sponsors are Astex Pharmaceuticals, Inc., Astex Pharmaceuticals, and Otsuka Pharmaceutical Co., Ltd.
There are two US patents protecting this investigational drug and forty-four international patents.
Summary for ASTX660
| US Patents | 2 |
| International Patents | 44 |
| US Patent Applications | 8 |
| WIPO Patent Applications | 4 |
| Japanese Patent Applications | 2 |
| Clinical Trial Progress | Phase 1 (2015-07-01) |
| Vendors | 33 |
Recent Clinical Trials for ASTX660
| Title | Sponsor | Phase |
|---|---|---|
| A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL) | Astex Pharmaceuticals, Inc. | Phase 1/Phase 2 |
| Tolinapant and Radiation for Cisplatin-Ineligible, Previously Untreated, Locally Advanced Head and Neck Cancer | Astex Pharmaceuticals, Inc. | Early Phase 1 |
| Tolinapant and Radiation for Cisplatin-Ineligible, Previously Untreated, Locally Advanced Head and Neck Cancer | Emory University | Early Phase 1 |
Clinical Trial Summary for ASTX660
Top disease conditions for ASTX660
Top clinical trial sponsors for ASTX660
US Patents for ASTX660
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| ASTX660 | ⤷ Sign Up | Bicyclic heterocycle compounds and their uses in therapy | ASTEX THERAPEUTICS LIMITED (Cambridge, GB) | ⤷ Sign Up |
| ASTX660 | ⤷ Sign Up | Bicyclic heterocycle compounds and their uses in therapy | ASTEX THERAPEUTICS LIMITED (Cambridge, GB) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for ASTX660
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| ASTX660 | Argentina | AR098838 | 2033-12-20 | ⤷ Sign Up |
| ASTX660 | Australia | AU2014369446 | 2033-12-20 | ⤷ Sign Up |
| ASTX660 | Australia | AU2019200840 | 2033-12-20 | ⤷ Sign Up |
| ASTX660 | Brazil | BR112016014561 | 2033-12-20 | ⤷ Sign Up |
| ASTX660 | Canada | CA2933939 | 2033-12-20 | ⤷ Sign Up |
| ASTX660 | China | CN105829310 | 2033-12-20 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
